Unicycive Therapeutics (NASDAQ:UNCY – Get Free Report)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a research report issued to clients and investors on Wednesday, Benzinga reports. They presently have a $4.50 price target on the stock. HC Wainwright’s price objective points to a potential upside of 437.76% from the […]